ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorWest China Hospital

About this trial

Severe radiation dermatitis remains a challenging complication in head and neck cancer with limited treatment options; this study aims to evaluate a novel Prussian blue-based nanozyme combined with near-infrared thermotherapy to promote effective healing of Grade III lesions.

Eligibility criteria

Qualifiers

Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;

Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.

Disqualifiers

Eastern Cooperative Oncology Group performance status of >2;

Pre-existing skin rash, ulceration or open wound in the treatment area;

Known allergy to trolamine or prussian blue;

Inflammatory or connective tissue disorder of the skin;

Trial design

Treatments tested in this trial

  • Photo-responsive nanozyme

Treatment groups

5 Participants
are divided into 1 treatment group

Sponsors and collaborators